Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients

Deborah Yamamura, Rasim Gucalp, Penelope Carlisle, Michael Cimino, Jeremy Roberts, Coleman Rotstein

Research output: Contribution to journalArticle

71 Scopus citations

Abstract

An open-label randomized trial comparing the efficacy and safety of cefepime versus piperacillin plus gentamicin (P+G) given intravenously for the treatment of febrile episodes in neutropenic patients with underlying malignancy was conducted at two oncology centers. Over a 30-month period 111 patients were enrolled and 99 patients were found to be suitable for evaluation. At the 72-h time of evaluation, cefepime monotherapy and P+G combination therapy produced comparable clinical response rates (78% for both). P+G and cefepime produced comparable response rates in microbiologically documented (78 versus 71%), clinically documented (100 versus 100%); and possible (75 versus 79%) infections. The P+G and cefepime treatments achieved comparable microbiological eradication of gram-negative (100 versus 71%) (P = 0.09) and gram-positive (44 versus 70%) (P = 0.37) organisms. There were no statistically significant differences in the rates of superinfection between the groups; however, more superinfections of fungal origin were noted in the P+G group. Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy. Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients.

Original languageEnglish (US)
Pages (from-to)1704-1708
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume41
Issue number8
DOIs
StatePublished - Aug 1997

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients'. Together they form a unique fingerprint.

  • Cite this